Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study

被引:99
作者
Akahira, JI [1 ]
Yoshikawa, H
Shimizu, Y
Tsunematsu, R
Hirakawa, T
Kuramoto, H
Shiromizu, K
Kuzuya, K
Kamura, T
Kikuchi, Y
Kodama, S
Yamamoto, K
Sato, S
机构
[1] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 9808574, Japan
[2] Canc Inst Hosp, Dept Obstet & Gynecol, Tokyo, Japan
[3] Natl Canc Ctr, Dept Obstet & Gynecol, Tokyo 104, Japan
[4] Kyushu Univ, Sch Med, Dept Obstet & Gynecol, Fukuoka 812, Japan
[5] Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Sagamihara, Kanagawa 228, Japan
[6] Saitama Canc Ctr, Dept Obstet & Gynecol, Saitama, Japan
[7] Aichi Canc Ctr Hosp, Dept Obstet & Gynecol, Nagoya, Aichi 464, Japan
[8] Kurume Univ, Sch Med, Dept Obstet & Gynecol, Kurume, Fukuoka 830, Japan
[9] Natl Def Med Ctr, Dept Obstet & Gynecol, Tokorozawa, Saitama, Japan
[10] Nagaoka Red Cross Hosp, Dept Obstet & Gynecol, Nagaoka, Niigata, Japan
[11] Kinki Univ, Sch Med, Dept Obstet & Gynecol, Osaka 589, Japan
[12] Univ Tokyo, Sch Med, Dept Obstet & Gynecol, Tokyo 113, Japan
关键词
ovarian cancer; stage IV; prognostic factor;
D O I
10.1006/gyno.2001.6172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. In the present study, we conducted a multicenter retrospective analysis to elucidate the prognostic factors of stage TV epithelial ovarian cancer. Methods. In November 1999, 24 Japanese institutions received questionnaires regarding stage IV epithelial ovarian cancer patients. Eligibility criteria included all patients with stage TV epithelial ovarian cancer who were surgically confirmed and initially treated in each institution between January 1990 and December 1997. Data were collected regarding age, performance status, tumor histologic subtype, site of metastasis, preoperative CA125, cytoreductive surgery, residual disease after cytoreductive surgery, and response to primary chemotherapy. Survival analysis and comparisons were performed by univariate and multivariate methods. Results. Two hundred twenty-five patients with stage IV ovarian cancer were identified. The median age of the patients was 54 years. The most common site of extraperitoneal disease was malignant pleural effusion (39.6%). Of the 225 patients who underwent an attempt at surgical debulking, 70 (31.1%) were optimally cytoreduced. Most patients received platinum-based combination chemotherapy for primary chemotherapy. In multivariate analysis, performance status, histology, and residual disease after cytoreductive surgery were independent prognostic predictors of outcome. The overall median survival for optimally debulked patients was 32 months compared to 16 months for suboptimally debulked patients (P < 0.0001, hazard ratio: 0.415). Conclusion. Optimal surgical debulking, performance status, and histology appear to be important prognostic factors of survival in patients with stage IV epithelial ovarian cancer. (C) 2001 Academic Press.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 26 条
  • [1] [Anonymous], WHO PUBL
  • [2] [Anonymous], J R STAT SOC
  • [3] Natural history of stage IV epithelial ovarian cancer
    Bonnefoi, H
    A'Hern, RP
    Fisher, C
    Macfarlane, V
    Barton, D
    Blake, P
    Shepherd, JH
    Gore, ME
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 767 - 775
  • [4] Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
    Bookman, MA
    McGuire, WP
    Kilpatrick, D
    Keenan, E
    Hogan, WM
    Johnson, SW
    ODwyer, P
    Rowinsky, E
    Gallion, HH
    Ozols, RF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1895 - 1902
  • [5] Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer
    Bristow, RE
    Montz, FJ
    Lagasse, LD
    Leuchter, RS
    Karlan, BY
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 72 (03) : 278 - 287
  • [6] Stage IV ovarian cancer: Impact of surgical debulking
    Curtin, JP
    Malik, R
    Venkatraman, ES
    Barakat, RR
    Hoskins, WJ
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 9 - 12
  • [7] LONG-TERM SURVIVAL IN ADVANCED OVARIAN-CANCER AFTER CYTOREDUCTION AND CHEMOTHERAPY TREATMENT
    DELCAMPO, JM
    FELIP, E
    RUBIO, D
    VIDAL, R
    BERMEJO, B
    COLOMER, R
    ZANON, V
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 53 (01) : 27 - 32
  • [8] Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
    Goff, BA
    delaCuesta, RS
    Muntz, HG
    Fleischhacker, D
    Ek, M
    Rice, LW
    Nikrui, N
    Tamimi, HK
    Cain, JM
    Greer, BE
    Fuller, AF
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 60 (03) : 412 - 417
  • [9] THE ROLE OF CYTOREDUCTIVE SURGERY IN THE MANAGEMENT OF STAGE-IV EPITHELIAL OVARIAN-CARCINOMA
    GOODMAN, HM
    HARLOW, BL
    SHEETS, EE
    MUTO, MG
    BROOKS, S
    STELLER, M
    KNAPP, RC
    BERKOWITZ, RS
    [J]. GYNECOLOGIC ONCOLOGY, 1992, 46 (03) : 367 - 371
  • [10] THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON RECURRENCE-FREE INTERVAL AND SURVIVAL IN SMALL-VOLUME STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    HOSKINS, WJ
    BUNDY, BN
    THIGPEN, JT
    OMURA, GA
    [J]. GYNECOLOGIC ONCOLOGY, 1992, 47 (02) : 159 - 166